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Significance: Aortic arch (AA) atheroma and AA atheroma progression are independent risk 
factors for recurrent vascular events in stroke/transient ischemic attack (TIA) patients. Total 
homocysteine level (tHcy) is an independent risk marker for atherosclerosis including that 
found in AA. The purpose of this study was to prospectively test the association between AA 
atheroma progression and tHcy. Methods: This is a cohort study of 307 consecutive hospitalized 
stroke/TIA patients undergoing transesophageal echocardiogram (TEE) as a part of their clinical 
workup. Measurable AA atheroma was detected in 167 patients of whom 125 consented to 
a protocol-mandated follow-up TEE at 12 months. Patients had evaluation for vascular risk 
factors, dietary factors (folate, B12 and pyridoxine), and methylene tetrahydrofolate reductase 
(MTHFR) polymorphism. One hundred eighteen stroke/TIA patients had tHcy, acceptable paired 
AA images, and detailed plaque measurements. An increase by ≥1 grade of AA atheroma 
was defined as progression. Results: Of the 118 patients, 33 (28%) showed progression 
and 17 (14%) showed regression of their index arch lesion at 1 year. tHcy (≥14.0 μmol/l) was 
significantly associated with progression on both univariate (RR = 3.4, 95% CI 2.0–5.8) and 
multivariate analyses (adjusted RR = 3.6, 95% CI 2.2–4.6). The changes in AA plaque thickness 
(r2 = 0.11; p < 0.001) and AA plaque area (r2 = 0.08; p = 0.002) correlated with tHcy. tHcy was 
associated with change in plaque thickness over 12 months, independent of age, dietary 
factors, renal function and MTHFR polymorphism (Standardized β-coefficient 0.335, p = 0.02). 
Conclusions: Our results validate the association and a linear correlation between tHcy and 
progression of AA atheroma.
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not been developed and factors that may influence the association 
between homocysteine and atherosclerosis such as diet and genetic 
polymorphism were not assessed.
In order to respond to these issues, we designed a prospective 
12-month study to analyze sequential changes in AA atheroma and 
to examine the role of stroke risk factors in promoting the progres-
sion of AA atheroma. Measurements of the rate of progression 
were obtained at two time points by using standardized criteria to 
quantitate plaque thickness and measure sectional areas. In order 
to ensure accurate sequential measurements at the same location, 
we established imaging landmarks in each segment.
Hyperhomocysteinemia is an independent risk factor for 
atherosclerotic vascular disease including cerebrovascular disease 
(Coull et al., 1990; Stampfer et al., 1992; Malinow et al., 1993; 
Spence et al., 1999), coronary artery disease (Stampfer et al., 
1992), peripheral vascular disease (Malinow et al., 1989), and 
aortic plaque thickness (Konecky et al., 1997; Tribouilloy et al., 
2000). Common factors known to influence homocysteine levels 
are age, intake of vitamin B12, folic acid levels, and genetic meth-
ylene tetrahydrofolate reductase (MTHFR) polymorphism (Kaul 
et al., 2006). Therefore, an additional objective of this study was 
IntroductIon
Significant aortic arch (AA) atheroma is the second most prevalent 
cardioembolic risk factor for stroke after atrial fibrillation, and is 
present in 16–20% of all stroke and transient ischemic attack (TIA) 
patients (Sen et al., 2000; Cheitlin et al., 2003). While there is no 
definitive treatment (Tunick and Kronzon, 2000), AA atheroma is 
an independent risk factor for new and recurrent stroke (Amarenco 
et al., 1994; The French Study of Aortic Plaques in Stroke Group, 
1996). Recently, we have shown that AA atheroma progression is 
an independent risk factor for recurrent vascular events in stroke/
TIA patients (Sen et al., 2007). Detection and measurement of AA 
atheroma is a safe procedure in stroke/TIA patients using the well-
established, validated, and cost-effective method of transesopha-
geal echocardiogram (TEE) (Daniel et al., 1991; McNamara et al., 
1997; Cheitlin et al., 2003). In a retrospective analysis of sequential 
TEE data, we have shown that AA atheroma has a high rate of 
progression (Sen et al., 2002); in 29% of stroke/TIA patients AA 
atheroma worsened ≥1 grade in 9 months compared to <10% that 
worsened annually in the carotid arteries (Olin et al., 1998; Liapis 
et al., 2000; Schminke et al., 2000). The study was limited by the fact 
that methods to control for the location of those measurements had 
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plaque progression and regression in the ascending (κ = 0.77), 
arch (κ = 0.85) and descending segment (κ = 0.86) of thoracic 
aorta. Excellent intraobserver reliabilities were noted for the first 
observer (κ = 0.93–1.00) and the second observer (κ = 0.91–0.94). 
Addition to grading of plaque thickness, cross-sectional plaque area 
was measured by tracing the outline of the atheroma as described 
by Khoury et al. (1998) and Ti et al. (2003).
demographIcs, rIsk Factors and etIology oF stroke
Cerebrovascular risk factors were classified as follows: age was based 
on the age at the time of presentation for initial TEE and dichot-
omized around a mean age of 65 years; hypertension was based on a 
previous diagnosis or prescription of anti-hypertensive medication; 
diabetes was based on a previous diagnosis with or without treatment 
with an anti-diabetic agent; hypercholesterolemia was based on a pre-
vious diagnosis or prescription of cholesterol-lowering medications; 
a cigarette smoker was defined as smoking 1 cigarette daily. A TIA was 
defined as a brief episode of neurologic dysfunction caused by focal 
brain or retinal ischemia, with clinical symptoms typically lasting 
less than 1 h, and without evidence of acute infarction on diffusion 
MRI scan (Albers et al., 2002). Patients suspected of complicated 
migraine, seizures or presenting with vague neurological symptoms 
were excluded. Stroke was defined as a persistent neurological defi-
cit of sudden onset (non-convulsive) lasting more than 24 h with 
confirmation by infarction noted on diffusion weighted MRI or 
follow-up CT, when MRI was not feasible (example Pacemaker). 
Stroke etiology was classified using the Trial of Org 10172 in Acute 
Stroke Treatment (TOAST) criteria (Adams et al., 1993).
homocysteIne measurement
Patients without renal failure (creatinine ≤2.5 mg/dl) were included 
for assessment of fasting plasma homocysteine level (tHcy). None 
were taking medications (example: Dilantin) known to elevate tHcy. 
Fasting blood samples were transported on ice and plasma sepa-
rated and stored at 4°C until measurement of total tHcy using high 
performance liquid chromatography with fluorescence detection.
mthFr polymorphIsm
Following informed consent, blood samples were col-
lected and genomic DNA was extracted (Puregene 
Systems, Gentra). The MTHFR polymorphism was geno-
typed as previously described by PCR using the follow-
ing primers: 5′-TGAAGGAGAAGGTGTCTGCGGGA-3′ and 
5′-AGGACGGTGCGGTGAGAGTG-3′ (Frosst et al., 1995). A 198 
base pair (bp) product is amplified and following digestion with 
Hinf1 (New England Biolabs), the common “C” allele of the C677T 
polymorphism remains undigested (Frosst et al., 1995). However, 
digestion of the PCR product containing the “T” polymorphism 
results in the generation of two fragments (175 and 23 bp) which 
are resolved by gel electrophoresis (6% polyacrylamide gel). The 
allele frequency was obtained by direct gene counting.
dIetary assessment usIng Food Frequency questIonnaIre
The Block FFQ, a validated questionnaire (Subar et al., 2001) was 
administered to all study patients. The 1998 version of the full-
diet Block FFQ (Block98) was used to convert information on 
food and supplement consumption to average daily energy and 
to assess whether the association between homocysteine and AA 
atheroma progression is independent of these determinants of 
homocysteine level.
materIals and methods
Three hundred and seven consecutive patients with stroke/TIA 
underwent TEE assessment within 1 month of symptom onset, as 
a part of their clinical evaluation to determine stroke etiology. All 
patients received a brain CT and/or MRI to confirm the diagnosis of 
stroke, had assessment of stroke risk factors, and were classified into 
stroke sub-types based on clinical assessment of etiology. Exclusion 
criteria were: absence of measurable aortic atheroma on the first 
TEE, age <18 years, intracerebral hemorrhage, subarachnoid hemor-
rhage, coma and serious medical conditions limiting life expectancy. 
Of these patients, 167 had evidence of aortic atheroma (measur-
able plaque ≥1 mm in ascending, arch or descending segment) and 
125/167 eligible patients consented to a protocol-mandated follow-up 
TEE at 12 months. One hundred eighteen (79 strokes and 39 TIAs) 
had adequate paired aortic images allowing detailed measurements 
of the AA plaque. Qualifying patients underwent a fasting plasma 
homocysteine level measurement as part of their stroke risk assess-
ment at the time of admission for the index cerebrovascular event 
prior to the initial TEE. Of these 118 patients, 116 provided blood 
samples for assessment of MTHFR polymorphism and 110 filled out 
a self-administered food frequency questionnaire (FFQ) just prior to 
the 12-month TEE. All patients enrolled in the study signed informed 
consent and the study was approved by the Biomedical Institutional 
Review Board of the University of North Carolina at Chapel Hill.
tee assessment oF aa atheroma
A comprehensive TEE with detailed imaging of the aorta was per-
formed using a Hewlett-Packard 21364A omniplane probe. Details 
of the imaging procedure and quantification of AA atheroma have 
been previously described (Sen et al., 2000). Briefly, the proximal 
and mid-ascending aorta were imaged at a probe depth of approxi-
mately 30 cm with a multi-plane angle of 100–150° to view the ves-
sel in the long axis. Examination of the descending thoracic aorta 
was accomplished by advancing the probe to the distal esophagus, 
imaging the aorta in cross-section (at 0°), and then slowly with-
drawing the probe to image the more proximal segments. As the 
transducer reached the AA, the multi-plane angle was rotated to 
between 0° and 90° to acquire sequential short axis views.
Digital images were acquired of the diseased areas in each seg-
ment of the AA with annotation of the distance of the transducer 
from the incisors. Identical locations in the AA were evaluated 
on the 1-year examination, using the depth of the transducer, 
plaque morphology, and (when available) surrounding  anatomical 
 landmarks for guidance.
Two observers blinded to clinical data independently quanti-
fied atheroma size for each imaged segment. Plaque thickness was 
measured as the maximal thickness of the intimal and medial lay-
ers and graded as mild (<1 mm), moderate (1–3.9 mm), or severe 
(≥4 mm), using the criteria of Amarenco et al. (1994) AA atheroma 
progression was defined as an increase in maximal thickness of the 
plaque in the AA by ≥1 grade(s) and regression defined as a decrease 
in maximal thickness by ≥1 grade(s). There was good interobserver 
reliability between the two observers, in the assessment of aortic 
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level <14.0 mcm/l (0.08 ± 0.10 mm). The tHcy on baseline exami-
nation was higher (p = 0.001) in patients with progression of AA 
atheroma (14.6 ± 1.3 mcm/l) than in those without progression 
(9.7 ± 0.4 mcm/l). Although in a limited sample (N = 85), the conva-
lescent tHcy (measured >3 months from index event) was higher in 
patients with progression of AA atheroma (N = 27, 13.9 ± 1.6 mcm/l) 
than in those without progression (N = 58, 11.7 ± 0.9 mcm/l), the dif-
ference was not significant (p = 0.2). There were no significant differ-
ences between the progression and non-progression groups in total 
cholesterol (189 ± 44 vs. 184 ± 39 mg/dl), LDL cholesterol (111 ± 44 
vs. 105 ± 35 mg/dl), HDL cholesterol (51 ± 16 vs. 53 ± 17 mg/dl) and 
serum triglycerides (158 ± 130 vs. 149 ± 82 mg/dl).
The frequency of the MTHFR 677T allele in the 116 subjects that 
participated in the study was 0.328. There were 55 MTHFR 677C/C 
homozygotes (45.2%), 46 677C/T heterozygotes (44.1%), and 15 
677T/T homozygotes (10.7%). The observed MTHFR genotype 
frequencies did not deviate from those predicted by the Hardy-
Weinberg equilibrium (p = 0.38, NS). ANOVA showed that MTHFR 
genotype was not a significant determinant of plasma homocysteine 
concentration (p = 0.43).
Of the 118 subjects, nutritional data was available in 110 sub-
jects. Although the progression group had a higher mean energy 
intake (1546 kCal) compared with those who did not progress 
(mean energy intake = 1306 kCal), the difference did not attain 
statistical significance (p = 0.1). There was no significant differ-
ence between the progression and no-progression groups in the 
energy adjusted folate (295 vs. 287 mcg, p = 0.69), energy adjusted 
pyridoxine (1.48 vs. 1.42 mg, p = 0.65) and energy adjusted Vitamin 
B12 (3.22 vs. 3.77 μg, p = 0.30).
There was no significant correlation (r2 = 0.01, p = 0.31) between 
baseline AA plaque thickness on initial TEE and fasting plasma 
homocysteine level. Also, a significant correlation (r2 = 0.01, 
nutrient intake using values from the USDA Nutrient Database for 
Standard. The Block 98 is an eight-page, scannable, quantitative 
instrument that includes 109 food and beverage items (including 
alcohol) and three multiple and nine single vitamin and mineral 
supplement items; We chose to examine intake of folic acid, vitamin 
B12, and pyridoxine in this analysis because of their importance in 
 homocysteine metabolism.
statIstIcal analysIs
Continuous variables describing demographic characteristics and bio-
chemical parameters were expressed as mean ± standard deviation. 
Univariate analysis using the Chi square test and Risk Ratio (RR) anal-
ysis investigated the association between each stroke risk factor and 
progression of AA atheroma. Subsequently, multiple logistic regres-
sion and adjusted Relative Risk (adj. RR) analysis explored the associa-
tion between AA atheroma progression and all stroke risk factors using 
methods described by Zhang and Yu (1998). This allows assessment 
of whether stroke risk factors independently increased the chance of 
detecting progression of AA atheroma by TEE. Kolmogorov–Smirnov 
(K–S) test was used to assess normality of distribution of continu-
ous variables. The variables that deviated from normal distribution 
were log-transformed prior to conducting tests applicable to normally 
distributed variables. Linear regression analysis was used to test the 
association between tHcy and interval change in plaque thickness as 
well as cross-sectional plaque area, measured on the sequential TEEs. 
Multiple linear regression analysis was used to test if the association 
between tHcy and AA atheroma progression was independent of 
determinants of tHcy including age, intake of vitamin B12, folic acid 
levels, and genetic MTHFR polymorphism. Statistical analysis was 
performed using SAS version 9.1.3 (Cary, NC, USA).
results
The characteristics of the 118 patients who had a protocol- mandated 
follow-up TEE are described in Table 1. They had a mean age of 
65 ± 12 years; 53% were males and 25% were black. The majority 
had a history of hypertension or elevated cholesterol, while smaller 
proportions had diabetes mellitus, history of recent tobacco use, or 
elevated homocysteine levels. On the baseline study, the largest lesion 
was mild in 8 (7%), moderate in 72 (61%) and severe in 38 (32%). 
Of these 118 patients, 33 (28%) showed progression and 16 (14%) 
had regression of their index lesion at 1 year. Among the 85 patients 
who did not progress, there were no significant differences between 
the sub-group of patients who regressed (N = 16) and those who did 
not (N = 69) in stroke risk factors including lipid profiles and fasting 
homocysteine levels. Hence this entire group (N = 85) is justifiably 
compared with the progression group (N = 33). Laboratory param-
eters including tHcy were assessed at similar time intervals (p = 0.91) 
from the index event among the progression group (2.8 ± 7.3 days) 
and the no-progression group (3.0 ± 7.2 days). Among the stroke 
risk factors, age ≥65 years, hypertension, diabetes, high cholesterol 
and smoking were not associated with atherosclerotic progression 
(Figure 1). Only tHcy (≥14.0 μmol/l) was significantly associated 
with progression on both univariable (RR = 3.4, 95% CI 2.0–5.8) 
and multivariable analysis (RR = 3.6, 95% CI 2.2–4.6, adjusted 
for the vascular risk factors). The change in plaque thickness over 
12 months was higher (p < 0.0001) in patients with homocysteine 
level ≥14.0 mcm/l (0.90 ± 0.22 mm) than those with homocysteine 
Table 1 | Baseline clinical characteristics of stroke/TIA patients (N = 118, 
79 strokes and 39 TIAs) assessed for progression of aortic arch 
atheroma.
Risk factors Stroke/TIA patients 
 (N = 118)






Total cholesterol (mg/dl) 185 ± 40
 LDL (mg/dl) 106 ± 38
 HDL (mg/dl) 53 ± 17
 Triglycerides (mg/dl) 151 ± 97
Smokers 27 (23%)
Alcohol use 23 (20%)
CAD 37 (31%)
Atrial fibrillation 12 (10%)
PVD 20 (17%)
Hyperhomocysteinemia 29 (25%)
Homocysteine level (mcm/l) 11.1 ± 5.4
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FIguRe 1 | Results of uni- and multivariable analysis investigating the contribution of vascular risk factors to AA plaque progression (≥1 grade over a 
period of 12 months) in patients with stroke and TIA.
p = 0.29) was not noted between baseline AA plaque area and fast-
ing plasma homocysteine level. However, a correlation (r2 = 0.11; 
p < 0.001) between baseline fasting homocysteine levels and the 
change (∆) in AA plaque thickness was observed, as shown in 
Figure 2A. Likewise, there was a correlation (r2 = 0.08; p = 0.002) 
between baseline fasting homocysteine levels and the change (∆) 
in AA plaque area, as shown in Figure 2B. Plasma tHcy was associ-
ated with change in plaque thickness over 12 months, independent 
of age, dietary factors, renal function and MTHFR polymorphism 
(Standardized β-coefficient 0.335, p = 0.02) as noted in Table 2.
dIscussIon
This 12-month study indicates that AA atheroma is a dynamic 
process: 28% of stroke/TIA patients showed plaque progression 
and 14% experienced regression. It confirms our prior finding 
that progression of AA atheroma is associated with hyperhomo-
cysteinemia (≥14.0 μmol/l) and that these changes were not influ-
enced by traditional vascular stroke risk factors. In that study, we 
reported a higher rate of progression (37%) and regression (22%); 
however, a composite of changes were measured in the ascending, 
arch, and descending thoracic aorta. When patients with changes 
only in the arch were selected, progression was noted in 29% and 
 regression in 9%, similar to the present study. The present study 
has the advantage of a prospective design utilizing methodologi-
cal details discussed earlier, aimed at improving the accuracy of 
measurement of aortic plaque.
Montgomery et al. prospectively re-evaluated 30 patients with 
moderate to severe aortic plaque noted on initial biplanar or 
multiplanar TEE (obtained as part of a workup for cardiac disease 
or an embolic event). Over an average of a 1-year period, progres-
sion was reported in 23% and regression in 10% (Montgomery 
et al., 1996). In a small group of 16 patients with familial hyper-
cholesterolemia taking pravastatin, Pistavos et al. (1998) using 
monoplanar TEE noted a rate of progression of 19% and a rate 
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and electron-beam CT (EBCT) have been shown to be promis-
ing approaches to measure AA progression (Rumberger, 2001; 
Takahashi and Stanford, 2005; Corti, 2006). Several studies testing 
the effect of statins and lipid lowering agents have used MRI to 
image changes in the thoracic aorta (Pistavos et al., 1998; Corti 
et al., 2005; Yonemura et al., 2005). Yet, none of these studies have 
reported the association of AA progression with tHcy.
Nevertheless, all prior studies utilizing transesophageal imag-
ing to evaluate AA atheroma suffer from similar limitations. Use 
of a grading system may limit the ability to detect progression or 
regression of AA atheroma due to a “ceiling effect.” For example, an 
aortic plaque of 4.6 mm thickness progressing to a thickness of 7 
or 8 mm may be graded as severe in both instances and hence may 
be incorrectly regarded as not to have progressed. Secondly, use of 
thickness as the only variable does not consider the effect of aortic 
remodeling that is associated with atherosclerosis. Age related loss 
of elasticity frequently results in distention and unfolding of the 
AA and accompanies aortic atherosclerosis (Shimojo et al., 1991). 
Hence, use of plaque area may be a better means of quantification 
compared to IMT in terms of capturing these modeling changes.
The current study has a few limitations that merit com-
ment. First, generalizability may be limited by the requirement 
that individuals with stroke/TIA have evidence of ≥1 mm aortic 
atheroma on initial TEE and agree to a follow-up TEE, 12 months 
later. Second, as TEE is a semi-invasive test, measurements of AA 
atheroma were not performed at intermediate time points. Third, 
the lack of association between traditional risk factors and change 
in plaque thickness may indicate a lack of sufficient power to detect 
such relationships. Alternatively, treatment of hypertension, dia-
betes and hypercholesterolemia may have modified the impact of 
these risk factors. Finally, multivariable logistic regression models 
can generally handle 1 predictor for every 8–10 outcome events. 
With only 33 patients demonstrating progression of AA atheroma 
and inclusion of six covariates in the model, there may be a concern 
about over-fitting. This is unlikely as using fewer (≤4) covariates in 
of regression of 38% over 2 years. More recently Geraci and 
Weinberger (2000), using supraclavicular B-mode ultrasonog-
raphy of the proximal AA in 89 patients evaluated for transient 
neurological symptoms or dizziness, noted a progression rate of 
19% and a regression rate of 18% over an average of 7.7 months 
(range 3–18 months). Compared to these studies, we report a 
similar rate of progression (28%). Parenthetically, in the extrac-
ranial carotid arteries, atheroma appears to progress at a lesser 
rate over longer follow-up. Thus, in the internal carotid artery a 
progression rate of 15–19% has been reported over 1.5–3.0 years 
(Olin et al., 1998; Liapis et al., 2000; Schminke et al., 2000). These 
studies do not report regression of carotid atheroma. The risk fac-
tors associated with atheroma progression were not investigated 
in any of these reports. Our rate of regression of AA atheroma 
noted on TEE (14%) is similar to that reported in the initial 
TEE series (10%) (Montgomery et al., 1996), but is lower than 
that reported in patients on statins (Pistavos et al., 1998). Newer 
imaging modalities including MRI, Multi-detector CT (MDCT) 
FIguRe 2 | (A) A correlation (r2 = 0.11, p < 0.001) was noted between the change (∆) in AA plaque thickness over a 12-month interval and fasting plasma homocysteine 
level (log-transformed), depicted in a semi-log scatter plot. (B) A correlation (r2 = 0.08, p = 0.002) was noted between the change (∆) in AA plaque area over a 12-month 
interval and fasting plasma homocysteine level (log-transformed), depicted in a semi-log scatter plot.
Table 2 | Covariates which may influence tHcy and its association with 
the change in AA plaque thickness over 12 months (dependent 






Dietary B12 intakea −0.046 0.805
Dietary folate intake −0.074 0.792
Dietary pyridoxine intake 0.227 0.415
MTHFR genotype (677 TT) 0.151 0.228
Homocysteinea 0.335 0.022
aLog-transformed.
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